PT1230354E - Linha celular permanente de amniocitos sua producao e sua utilizacao para a producao de vectores de transferencia de genes - Google Patents

Linha celular permanente de amniocitos sua producao e sua utilizacao para a producao de vectores de transferencia de genes

Info

Publication number
PT1230354E
PT1230354E PT00979539T PT00979539T PT1230354E PT 1230354 E PT1230354 E PT 1230354E PT 00979539 T PT00979539 T PT 00979539T PT 00979539 T PT00979539 T PT 00979539T PT 1230354 E PT1230354 E PT 1230354E
Authority
PT
Portugal
Prior art keywords
die
production
amniozyten
der
von
Prior art date
Application number
PT00979539T
Other languages
English (en)
Inventor
Stefan Kochanek
Gudrun Schiedner
Original Assignee
Cevec Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cevec Pharmaceuticals Gmbh filed Critical Cevec Pharmaceuticals Gmbh
Publication of PT1230354E publication Critical patent/PT1230354E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351Methods of production or purification of viral material
    • C12N2710/10352Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/30Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/40Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/40Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405Vectors comprising RGD peptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018Adenoviridae
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Manufacturing Of Steel Electrode Plates (AREA)
PT00979539T 1999-11-18 2000-11-07 Linha celular permanente de amniocitos sua producao e sua utilizacao para a producao de vectores de transferencia de genes PT1230354E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19955558A DE19955558C2 (de) 1999-11-18 1999-11-18 Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren

Publications (1)

Publication Number Publication Date
PT1230354E true PT1230354E (pt) 2004-04-30

Family

ID=7929523

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00979539T PT1230354E (pt) 1999-11-18 2000-11-07 Linha celular permanente de amniocitos sua producao e sua utilizacao para a producao de vectores de transferencia de genes

Country Status (16)

Country Link
EP (1) EP1230354B1 (pt)
JP (1) JP4456790B2 (pt)
CN (1) CN100412201C (pt)
AT (1) ATE257512T1 (pt)
AU (1) AU784003B2 (pt)
CA (1) CA2391591C (pt)
CZ (1) CZ300124B6 (pt)
DE (2) DE19955558C2 (pt)
DK (1) DK1230354T3 (pt)
ES (1) ES2211647T3 (pt)
HU (1) HU227440B1 (pt)
IL (2) IL149291A0 (pt)
PL (1) PL205966B1 (pt)
PT (1) PT1230354E (pt)
TR (1) TR200400402T4 (pt)
WO (1) WO2001036615A2 (pt)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1528101A1 (en) * 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
EP1718738A2 (en) 2004-02-23 2006-11-08 Crucell Holland B.V. Virus purification methods
CN101155915B (zh) 2005-04-11 2013-12-04 克鲁塞尔荷兰公司 利用超滤进行病毒纯化
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
LT2061803T (lt) 2006-08-28 2019-11-25 Ares Trading Sa Fc turinčių baltymų gryninimo būdas
MX2011004292A (es) 2008-11-03 2011-05-31 Crucell Holland Bv Metodo para la produccion de vectores adenovirales.
DE102009003439A1 (de) 2009-02-05 2010-08-26 Cevec Pharmaceuticals Gmbh Neue permanente humane Zelllinie
KR101749779B1 (ko) 2009-10-15 2017-06-21 크루셀 홀란드 비.브이. 아데노바이러스 입자의 정제 방법
WO2011045381A1 (en) 2009-10-15 2011-04-21 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
JP5250155B2 (ja) 2010-02-15 2013-07-31 クルセル ホランド ベー ヴェー Ad26アデノウイルスベクターの製造方法
RU2565546C2 (ru) 2010-08-16 2015-10-20 Севек Фармасьютикалз Гмбх Постоянные линии клеток человека для получения вирусов гриппа
WO2013077645A1 (ko) * 2011-11-24 2013-05-30 주식회사 바이로메드 아데노바이러스 생산 신규 세포주 및 그의 용도
EA034284B1 (ru) 2012-03-12 2020-01-24 Янссен Вэксинс Энд Превеншн Б.В. Частицы рекомбинантного трансгенсодержащего аденовируса с 5'-концевыми нуклеотидами ctatctat
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
BR112014023196B1 (pt) 2012-03-22 2021-09-08 Janssen Vaccines & Prevention B.V. Vacinas contra o vírus sincicial respiratório (rsv), seu método de produção, e ácido nucleico recombinante isolado
EP2662451A1 (en) * 2012-05-07 2013-11-13 Stefan Kochanek Nucleic acid construct and use of the same
US20150259387A1 (en) * 2012-10-19 2015-09-17 Cevec Pharmaceuticals Gmbh Production of a hcmv based vaccine in human amniocyte cell lines
EP2722337A1 (en) 2012-10-19 2014-04-23 CEVEC Pharmaceuticals GmbH Production of a HCMV based vaccine in human amniocyte cell lines
MX361774B (es) 2013-04-25 2018-12-17 Janssen Vaccines & Prevention Bv Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados.
SG11201510216RA (en) 2013-06-17 2016-01-28 Crucell Holland Bv Stabilized soluble pre-fusion rsv f polypeptides
WO2015000856A1 (de) 2013-07-01 2015-01-08 Charité - Universitätsmedizin Berlin Immortalisierte humane chorionzelllinie sowie verfahren zur immortalisierung humaner chorionzellen
SG11201702997YA (en) 2014-11-04 2017-05-30 Janssen Vaccines & Prevention Bv Therapeutic hpv16 vaccines
EP3042952A1 (en) 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
CA2981841A1 (en) 2015-04-14 2016-10-20 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
CA2991540A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion respiratory syncytial sirus polypeptides
US10456462B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Preventions B.V. Vaccine against RSV
JP6470872B2 (ja) 2015-08-20 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. 治療用hpv18ワクチン
SI3439672T1 (sl) 2016-04-05 2021-02-26 Janssen Vaccines & Prevention B.V. Stabiliziran topen pre-fuzijski F protein RSV za uporabo v profilaksi okužbe z RSV
US10729757B2 (en) 2016-04-05 2020-08-04 Janssen Vaccines & Prevention B.V. Vaccine against RSV
WO2017192418A1 (en) 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Therapeutic hpv vaccine combinations
JP7046835B2 (ja) 2016-05-12 2022-04-04 ヤンセン ファッシンズ アンド プリベンション ベーフェー 強力でバランスのとれた双方向性プロモーター
CN109311946A (zh) 2016-05-30 2019-02-05 扬森疫苗与预防公司 稳定化的融合前rsv f蛋白
KR102307065B1 (ko) 2016-06-20 2021-09-30 얀센 백신스 앤드 프리벤션 비.브이. 강력하고 균형 잡힌 양방향성 프로모터
EP3484506A1 (en) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv vaccines
WO2018146205A1 (en) 2017-02-09 2018-08-16 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. Rsv感染に対する防御免疫を誘導するための方法及び組成物
US11229695B2 (en) 2017-09-15 2022-01-25 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
EA202091074A1 (ru) 2017-10-31 2020-07-22 Янссен Вэксинс Энд Превеншн Б.В. Аденовирус и его применения
SG11202003200VA (en) 2017-10-31 2020-05-28 Janssen Vaccines & Prevention Bv Adenovirus and uses thereof
JP7366014B2 (ja) 2017-10-31 2023-10-20 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルス及びその用途
US11459583B2 (en) 2017-10-31 2022-10-04 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
CA3126462A1 (en) 2019-01-10 2020-07-16 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP3736286A1 (en) 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
EP3969044A1 (en) 2019-05-15 2022-03-23 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
AU2020275910A1 (en) 2019-05-15 2021-11-04 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
WO2021043757A1 (en) 2019-09-02 2021-03-11 Biotest Ag Factor viii protein with increased half-life
JP2022551107A (ja) 2019-10-03 2022-12-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルスベクターおよびその使用
JOP20220116A1 (ar) 2019-11-18 2023-01-30 Janssen Biotech Inc اللقاحات المستندة إلى الطافر calr وjak2 واستخداماتها
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
CN114929261A (zh) 2020-02-17 2022-08-19 生物测试股份公司 凝血因子viii的皮下施用
EP4176087A1 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
IL302046A (en) 2020-10-15 2023-06-01 Hoffmann La Roche Nucleic acid structures for va RNA transcription
CA3197726A1 (en) 2020-10-15 2022-04-21 Simon Auslaender Nucleic acid constructs for simultaneous gene activation
WO2023198685A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Method for determining aav genomes
WO2023227438A1 (en) 2022-05-23 2023-11-30 F. Hoffmann-La Roche Ag Raman-based method for the differentiation of aav particle serotype and aav particle loading status
WO2023232922A1 (en) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
WO2024013239A1 (en) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
WO2024056561A1 (en) 2022-09-12 2024-03-21 F. Hoffmann-La Roche Ag Method for separating full and empty aav particles
WO2024165456A1 (en) 2023-02-07 2024-08-15 F. Hoffmann-La Roche Ag Method for the detection of anti-aav particle antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994128A (en) * 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy

Also Published As

Publication number Publication date
PL205966B1 (pl) 2010-06-30
WO2001036615A2 (de) 2001-05-25
HUP0203387A2 (hu) 2002-12-28
CA2391591C (en) 2008-12-30
IL149291A0 (en) 2002-11-10
CN100412201C (zh) 2008-08-20
JP2003514526A (ja) 2003-04-22
HUP0203387A3 (en) 2005-07-28
JP4456790B2 (ja) 2010-04-28
ATE257512T1 (de) 2004-01-15
HU227440B1 (en) 2011-06-28
CZ20021709A3 (cs) 2002-08-14
AU1699001A (en) 2001-05-30
WO2001036615A3 (de) 2002-01-10
CA2391591A1 (en) 2001-05-25
IL149291A (en) 2008-11-26
DE50004995D1 (de) 2004-02-12
CN1433476A (zh) 2003-07-30
AU784003B2 (en) 2006-01-12
ES2211647T3 (es) 2004-07-16
CZ300124B6 (cs) 2009-02-18
DK1230354T3 (da) 2004-03-22
EP1230354A2 (de) 2002-08-14
EP1230354B1 (de) 2004-01-07
PL357495A1 (en) 2004-07-26
DE19955558A1 (de) 2001-06-07
DE19955558C2 (de) 2003-03-20
TR200400402T4 (tr) 2004-03-22

Similar Documents

Publication Publication Date Title
PT1230354E (pt) Linha celular permanente de amniocitos sua producao e sua utilizacao para a producao de vectores de transferencia de genes
SE9900100D0 (sv) New compounds
DE10084442T1 (de) Kaolin-Pigmente, ihre Herstellung und Verwendung
WO2003041664A1 (fr) Cosmetiques contenant un mineral argileux
DE59901597D1 (de) Dispergiermittel zur Herstellung wässriger Pigmentpasten
DE59101729D1 (de) Wasserunlösliche azofarbmittel, ihre herstellung und verwendung.
DE69801818D1 (de) Metallkomplex-Disazofarbstoffe, ihre Herstellung und Verwendung
ATE63110T1 (de) Farblose ketimine, ihre herstellung und ihre verwendung als vernetzungsmittel.
ATE161177T1 (de) An sigma-bindungsstellen wirkende stoffe
EP0785223A3 (de) Verwendung von Tensiden bei der Trocknung von hydrophilen, hochquellfähigen Hydrogelen
FI873312A (fi) Lim foer papper baserade pao fettalkyldiketener och katjoniska polyakrylamider och terpolymerisat av akrylamid, n-vinylimidazol och n-vinylimidazolin.
ITRM920384A1 (it) Procedimento per la produzione di leuco coloranti allo zolfo e prodotto ottenuto.
CA2272483A1 (en) Pyrazoles
NO874886D0 (no) Staal-baand eller -plate for trukne og glattede bokser, og fremstillingsmaate for samme.
TR200100142T2 (tr) R-(+)-6-Karboksamido-3-N-Metilamino-1,2,3,4- tetrahidrokarbazol üretimi için işlem.
EP1020448A3 (en) Arylheterocycles with herbicidal activity
EP0960898A3 (de) Suspensionen, ein Verfahren zu deren Herstellung und deren Verwendung
IT1306132B1 (it) Anodo perfezionato, procedimento per la sua fabbricazione eprocedimento per la produzione di alluminio.
BG104401A (en) Chloroacetamide mixtures with suppressed precipitation
Brimblecombe The History and Future Requirements of Air Quality Management
Adamski Engineers of the Future: PEs or PhDs\= Bidders or Proposers
WO2000066787A3 (en) Growth hormone-regulatable liver genes and proteins, and uses thereof
EP0292169A3 (en) Substrates for b-galactosidase
DE59101464D1 (de) Monoazofarbstoffe, ihre Herstellung und Verwendung.
Kim et al. The characterization and structure of $\varepsilon $-globin gene Perissodactyla